White paper

White paper: Adaptive Pathway Initiative

The Adaptive Pathway initiative ia an EMA project to examine the possibilty of incremental drug licensing in order to allow those most in need to access new medicines as soon as possible. Central to the concept is the use of Real World Data in the licensing process. Here we examine the status of the Adaptive Pathway Initiative using publically available information, with a specific focus on the RWD component.

Link To Evidence Note